Dr. Keating is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
MD Anderson Cancer Ctr, Unit 428
Houston, TX 77030Phone+1 713-792-6161
Education & Training
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1974 - 1975
University of Melbourne Faculty of MedicineClass of 1966
Certifications & Licensure
TX State Medical License 1975 - 2025
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- A Phase I/II Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a Genetic Approach Start of enrollment: 2001 Dec 01
- Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2008 Feb 01
Publications & Presentations
PubMed
- Topological Structures in the Space of Treatment-Naïve Patients with Chronic Lymphocytic Leukemia.Reginald L McGee 2nd, Jake Reed, Caitlin E Coombes, Carmen D Herling, Michael J Keating
Cancers. 2024-07-26 - 1 citationsGlobal miRNA profiling reveals key molecules that contribute to different chronic lymphocytic leukemia incidences in Asian and Western populations.Panpan Liu, Kefeng Wang, Jianan Li, Marcia A Ogasawara, Zhongjun Xia
Haematologica. 2024-02-01 - 13 citationsSustained remissions in CLL after frontline FCR treatment with very-long-term follow-up.Philip A Thompson, Alexandre Bazinet, William G Wierda, Constantine S Tam, Susan M O'Brien
Blood. 2023-11-23
Journal Articles
- Trisomy 12 Chronic Lymphocytic Leukemia Expresses a Unique Set of Activated and Targetable PathwaysMichael J Keating, Lynne V Abruzzo, Haematologica
- A Pilot Study of Lower Doses of Ibrutinib in Patients with Chronic Lymphocytic LeukemiaNitin Jain, Michael J Keating, Varsha Gandhi, William G Wierda, Blood
Press Mentions
What Options Are Available for CLL Patients Who Relapse After Ibrutinib?February 21st, 2019
Grant Support
- Clinical Research CoreNational Cancer Institute2006–2010
- Clinical ConsortiumNational Cancer Institute2000–2002
- Clinical ConsosrtiumNational Cancer Institute1999
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
